Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

This phase I trial tests the safety, side effects, and best dose of genetically engineered cells (CD83 chimeric antigen receptor \[CAR\] T cells) in treating patients with acute myeloid leukemia (AML) that has come back after a period of improvement (relapsed) or has not responded to previous treatment (refractory). CD83 is a protein that is found on AML blasts. Blasts are abnormal immature white blood cells that can multiply uncontrollably: filling up the bone marrow and preventing the production of other cells important for survival. CD83 CAR T cells represent a new cell therapy to eliminate

Trial Details

NCT ID
NCT06871410
Phase
PHASE1
Sponsor
Roswell Park Cancer Institute
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Autologous Anti-CD83 CAR T-cells
  • Biospecimen Collection
  • Chest Radiography
  • Computed Tomography
  • Cyclophosphamide
  • Echocardiography
Locations (sample)
  • Buffalo, New York, United States|42.88645,-78.87837

Key Eligibility Criteria

  • Age ≥ 18 years old.
  • Karnofsky performance status score ≥ 70%.
  • Relapsed or refractory AML.This can include detection of AML by morphologic, flow cytometric, or molecular means.(20).
  • Relapsed AML is defined as the reappearance of malignant blasts in the bone marrow, reappearance of malignant blasts in the peripheral blood, or de…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →